Get the Stockscreener App
4.27
0.47%
0.02
After Hours:
4.28
0.01
+0.23%
Neuphoria Therapeutics Inc stock is traded at $4.27, with a volume of 58,954.
It is up +0.47% in the last 24 hours and down -2.95% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$4.25
Open:
$4.33
24h Volume:
58,954
Relative Volume:
0.04
Market Cap:
$22.96M
Revenue:
$15.66M
Net Income/Loss:
$5.83M
P/E Ratio:
-0.1787
EPS:
-23.8939
Net Cash Flow:
$466.20K
1W Performance:
-5.53%
1M Performance:
-2.95%
6M Performance:
-40.28%
1Y Performance:
+0.00%
1-Day Range:
$4.25
$4.44
1-Week Range:
$4.10
$4.50
52-Week Range:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.27 | 22.96M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Neuphoria Therapeutics (NEUP) Stock Analysis Report | Financials & Insights - Benzinga
HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq
NEUP: Analyst Lowers Price Target by 66% but Maintains 'Buy' Rat - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. stock deliver strong dividend growthIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Neuphoria Therapeutics (NEUP) Considers Strategic Alternatives A - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer - Investing.com
Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium - marketscreener.com
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium - The Manila Times
Is Neuphoria Therapeutics Inc. stock near bottom after declineEarnings Risk Report & Weekly Top Stock Performers List - Newser
Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics - marketscreener.com
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders - Yahoo Finance
Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement - marketscreener.com
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program - MSN
Neuphoria responds to Lynx1’s proxy contest claims in board dispute By Investing.com - Investing.com Australia
Neuphoria Therapeutics (NEUP) Encourages Shareholders to Support Its Nominees - GuruFocus
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions - GlobeNewswire
Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital - MSN
Reviewing Neuphoria Therapeutics (NEUP) & The Competition - Defense World
What analysts say about Neuphoria Therapeutics Inc stockMACD Histogram Signals & Discover Your Financial Freedom Formula - earlytimes.in
Sell Signal: How Neuphoria Therapeutics Inc. stock reacts to global recession fearsSwing Trade & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Lynx1 Capital Management Solicits Proxies from Shareholders of Neuphoria Therapeutics - marketscreener.com
Neuphoria urges stockholders to vote for its nominees amid strategic review - Investing.com Nigeria
Neuphoria Therapeutics Sends Letter to Stockholders - marketscreener.com
Neuphoria Therapeutics (NEUP) Outlines Strategic Review Ahead of Annual Meeting - GuruFocus
Making the Most of Varied Backgrounds: Ogunbufunmi’s Bold Move Toward Technology Leadership - Bitget
Neuphoria urges stockholders to vote for its nominees amid strategic review By Investing.com - Investing.com South Africa
Neuphoria Therapeutics Inc. Sends Letter to Stockholders - Yahoo Finance
Why Did NEUP Stock Surge 64% Today? - MSN
What drives Neuphoria Therapeutics Inc stock priceStop Loss Placement Tips & Small Budget Growth - earlytimes.in
Tenax Therapeutics, Inc. (TENX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
How supply chain issues affect Neuphoria Therapeutics Inc. stock2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com
Will Neuphoria Therapeutics Inc. stock continue upward momentumMarket Movement Recap & Daily Oversold Stock Bounce Ideas - newser.com
What does recent volatility data suggest for Neuphoria Therapeutics Inc.2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
How Neuphoria Therapeutics Inc. stock performs in interest rate cyclesTrade Ideas & Fast Exit and Entry Strategy Plans - newser.com
What indicators show strength in Neuphoria Therapeutics Inc.Earnings Growth Report & Stepwise Swing Trade Plans - newser.com
How to read the order book for Neuphoria Therapeutics Inc.Weekly Trend Summary & Target Return Focused Picks - newser.com
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):